The Experts below are selected from a list of 51936 Experts worldwide ranked by ideXlab platform
Tae Hoon Shin - One of the best experts on this subject based on the ideXlab platform.
-
human umbilical cord blood mesenchymal stem cell derived pge2 and tgf β1 alleviate atopic dermatitis by reducing mast cell Degranulation
Stem Cells, 2015Co-Authors: Tae Hoon Shin, Kyung Rok Yu, Taewook Kang, Soon Won Choi, Kyungsun KangAbstract:Mesenchymal stem cell (MSC) is a promising tool for the therapy of immune disorders. However, their efficacy and mechanisms in treating allergic skin disorders are less verified. We sought to investigate the therapeutic efficacy of human umbilical cord blood-derived MSCs (hUCB-MSCs) against murine atopic dermatitis (AD) and to explore distinct mechanisms that regulate their efficacy. AD was induced in mice by the topical application of Dermatophagoides farinae. Naive or activated-hUCB-MSCs were administered to mice, and clinical severity was determined. The subcutaneous administration of nucleotide-binding oligomerization domain 2 (NOD2)-activated hUCB-MSCs exhibited prominent protective effects against AD, and suppressed the infiltration and Degranulation of mast cells (MCs). A β-hexosaminidase assay was performed to evaluate the effect of hUCB-MSCs on MC Degranulation. NOD2-activated MSCs reduced the MC Degranulation via NOD2-cyclooxygenase-2 signaling. In contrast to bone marrow-derived MSCs, hUCB-MSCs exerted a cell-to-cell contact-independent suppressive effect on MC Degranulation through the higher production of prostaglandin E2 (PGE2). Additionally, transforming growth factor (TGF)-β1 production from hUCB-MSCs in response to interleukin-4 contributed to the attenuation of MC Degranulation by downregulating FceRI expression in MCs. In conclusion, the subcutaneous application of NOD2-activated hUCB-MSCs can efficiently ameliorate AD, and MSC-derived PGE2 and TGF-β1 are required for the inhibition of MC Degranulation. Stem Cells 2015;33:1254–1266
-
human umbilical cord blood mesenchymal stem cell derived pge2 and tgf β1 alleviate atopic dermatitis by reducing mast cell Degranulation
Stem Cells, 2015Co-Authors: Hyung Sik Kim, Tae Hoon Shin, Taewook Kang, Soon Won Choi, Jun Won Yun, Sunghoon Lee, Byungchul Lee, Yoojin Seo, Seunghee Lee, Kwang Won SeoAbstract:Mesenchymal stem cell (MSC) is a promising tool for the therapy of immune disorders. However, their efficacy and mechanisms in treating allergic skin disorders are less verified. We sought to investigate the therapeutic efficacy of human umbilical cord blood-derived MSCs (hUCB-MSCs) against murine atopic dermatitis (AD) and to explore distinct mechanisms that regulate their efficacy. AD was induced in mice by the topical application of Dermatophagoides farinae. Naive or activated-hUCB-MSCs were administered to mice, and clinical severity was determined. The subcutaneous administration of nucleotide-binding oligomerization domain 2 (NOD2)-activated hUCB-MSCs exhibited prominent protective effects against AD, and suppressed the infiltration and Degranulation of mast cells (MCs). A β-hexosaminidase assay was performed to evaluate the effect of hUCB-MSCs on MC Degranulation. NOD2-activated MSCs reduced the MC Degranulation via NOD2-cyclooxygenase-2 signaling. In contrast to bone marrow-derived MSCs, hUCB-MSCs exerted a cell-to-cell contact-independent suppressive effect on MC Degranulation through the higher production of prostaglandin E2 (PGE2 ). Additionally, transforming growth factor (TGF)-β1 production from hUCB-MSCs in response to interleukin-4 contributed to the attenuation of MC Degranulation by downregulating FceRI expression in MCs. In conclusion, the subcutaneous application of NOD2-activated hUCB-MSCs can efficiently ameliorate AD, and MSC-derived PGE2 and TGF-β1 are required for the inhibition of MC Degranulation.
Hajime Karasuyama - One of the best experts on this subject based on the ideXlab platform.
-
Real-time imaging of mast cell Degranulation in vitro and in vivo.
Biochemical and Biophysical Research Communications, 2016Co-Authors: Kayo Horiguchi, Soichiro Yoshikawa, Asuka Saito, Salma Haddad, Takuya Ohta, Yoshinori Yamanishi, Kensuke Miyake, Hajime KarasuyamaAbstract:Abstract Mast cells undergo Degranulation in response to various stimuli and rapidly release pre-formed mediators present in secretory granules, leading to immediate-type allergic reactions. Mast cell Degranulation is commonly detected and quantified in vitro by measuring histamine or β-hexosaminidase released to culture medium. However, this type of assay cannot monitor Degranulation of individual cells in real time, and it is not suitable for in vivo detection of Degranulation. At the aim of real time imaging of mast cell Degranulation at single cell level, we here developed a fluorescent protein-based indicator of Degranulation, designated immuno-pHluorin (impH). When expressed in mast cells, impH is located in the membrane of secretory granules and non-fluorescent under homeostatic conditions while it turns fluorescent following Degranulation, due to the pH change inside of granules during exocytosis. impH enabled us to detect polarized Degranulation within one single cell when mast cells were stimulated via the small area of cell surface. Transplantation of impH-expressing mast cells into mast cell-deficient mice demonstrated that impH could function as a real-time indicator of Degranulation in vivo . Thus, impH is a useful tool for imaging of mast cell activation and Degranulation in vitro and in vivo , and may be applied for screening of reagents regulating mast cell Degranulation.
Kyungsun Kang - One of the best experts on this subject based on the ideXlab platform.
-
human umbilical cord blood mesenchymal stem cell derived pge2 and tgf β1 alleviate atopic dermatitis by reducing mast cell Degranulation
Stem Cells, 2015Co-Authors: Tae Hoon Shin, Kyung Rok Yu, Taewook Kang, Soon Won Choi, Kyungsun KangAbstract:Mesenchymal stem cell (MSC) is a promising tool for the therapy of immune disorders. However, their efficacy and mechanisms in treating allergic skin disorders are less verified. We sought to investigate the therapeutic efficacy of human umbilical cord blood-derived MSCs (hUCB-MSCs) against murine atopic dermatitis (AD) and to explore distinct mechanisms that regulate their efficacy. AD was induced in mice by the topical application of Dermatophagoides farinae. Naive or activated-hUCB-MSCs were administered to mice, and clinical severity was determined. The subcutaneous administration of nucleotide-binding oligomerization domain 2 (NOD2)-activated hUCB-MSCs exhibited prominent protective effects against AD, and suppressed the infiltration and Degranulation of mast cells (MCs). A β-hexosaminidase assay was performed to evaluate the effect of hUCB-MSCs on MC Degranulation. NOD2-activated MSCs reduced the MC Degranulation via NOD2-cyclooxygenase-2 signaling. In contrast to bone marrow-derived MSCs, hUCB-MSCs exerted a cell-to-cell contact-independent suppressive effect on MC Degranulation through the higher production of prostaglandin E2 (PGE2). Additionally, transforming growth factor (TGF)-β1 production from hUCB-MSCs in response to interleukin-4 contributed to the attenuation of MC Degranulation by downregulating FceRI expression in MCs. In conclusion, the subcutaneous application of NOD2-activated hUCB-MSCs can efficiently ameliorate AD, and MSC-derived PGE2 and TGF-β1 are required for the inhibition of MC Degranulation. Stem Cells 2015;33:1254–1266
Kwang Won Seo - One of the best experts on this subject based on the ideXlab platform.
-
human umbilical cord blood mesenchymal stem cell derived pge2 and tgf β1 alleviate atopic dermatitis by reducing mast cell Degranulation
Stem Cells, 2015Co-Authors: Hyung Sik Kim, Tae Hoon Shin, Taewook Kang, Soon Won Choi, Jun Won Yun, Sunghoon Lee, Byungchul Lee, Yoojin Seo, Seunghee Lee, Kwang Won SeoAbstract:Mesenchymal stem cell (MSC) is a promising tool for the therapy of immune disorders. However, their efficacy and mechanisms in treating allergic skin disorders are less verified. We sought to investigate the therapeutic efficacy of human umbilical cord blood-derived MSCs (hUCB-MSCs) against murine atopic dermatitis (AD) and to explore distinct mechanisms that regulate their efficacy. AD was induced in mice by the topical application of Dermatophagoides farinae. Naive or activated-hUCB-MSCs were administered to mice, and clinical severity was determined. The subcutaneous administration of nucleotide-binding oligomerization domain 2 (NOD2)-activated hUCB-MSCs exhibited prominent protective effects against AD, and suppressed the infiltration and Degranulation of mast cells (MCs). A β-hexosaminidase assay was performed to evaluate the effect of hUCB-MSCs on MC Degranulation. NOD2-activated MSCs reduced the MC Degranulation via NOD2-cyclooxygenase-2 signaling. In contrast to bone marrow-derived MSCs, hUCB-MSCs exerted a cell-to-cell contact-independent suppressive effect on MC Degranulation through the higher production of prostaglandin E2 (PGE2 ). Additionally, transforming growth factor (TGF)-β1 production from hUCB-MSCs in response to interleukin-4 contributed to the attenuation of MC Degranulation by downregulating FceRI expression in MCs. In conclusion, the subcutaneous application of NOD2-activated hUCB-MSCs can efficiently ameliorate AD, and MSC-derived PGE2 and TGF-β1 are required for the inhibition of MC Degranulation.
Taewook Kang - One of the best experts on this subject based on the ideXlab platform.
-
human umbilical cord blood mesenchymal stem cell derived pge2 and tgf β1 alleviate atopic dermatitis by reducing mast cell Degranulation
Stem Cells, 2015Co-Authors: Tae Hoon Shin, Kyung Rok Yu, Taewook Kang, Soon Won Choi, Kyungsun KangAbstract:Mesenchymal stem cell (MSC) is a promising tool for the therapy of immune disorders. However, their efficacy and mechanisms in treating allergic skin disorders are less verified. We sought to investigate the therapeutic efficacy of human umbilical cord blood-derived MSCs (hUCB-MSCs) against murine atopic dermatitis (AD) and to explore distinct mechanisms that regulate their efficacy. AD was induced in mice by the topical application of Dermatophagoides farinae. Naive or activated-hUCB-MSCs were administered to mice, and clinical severity was determined. The subcutaneous administration of nucleotide-binding oligomerization domain 2 (NOD2)-activated hUCB-MSCs exhibited prominent protective effects against AD, and suppressed the infiltration and Degranulation of mast cells (MCs). A β-hexosaminidase assay was performed to evaluate the effect of hUCB-MSCs on MC Degranulation. NOD2-activated MSCs reduced the MC Degranulation via NOD2-cyclooxygenase-2 signaling. In contrast to bone marrow-derived MSCs, hUCB-MSCs exerted a cell-to-cell contact-independent suppressive effect on MC Degranulation through the higher production of prostaglandin E2 (PGE2). Additionally, transforming growth factor (TGF)-β1 production from hUCB-MSCs in response to interleukin-4 contributed to the attenuation of MC Degranulation by downregulating FceRI expression in MCs. In conclusion, the subcutaneous application of NOD2-activated hUCB-MSCs can efficiently ameliorate AD, and MSC-derived PGE2 and TGF-β1 are required for the inhibition of MC Degranulation. Stem Cells 2015;33:1254–1266
-
human umbilical cord blood mesenchymal stem cell derived pge2 and tgf β1 alleviate atopic dermatitis by reducing mast cell Degranulation
Stem Cells, 2015Co-Authors: Hyung Sik Kim, Tae Hoon Shin, Taewook Kang, Soon Won Choi, Jun Won Yun, Sunghoon Lee, Byungchul Lee, Yoojin Seo, Seunghee Lee, Kwang Won SeoAbstract:Mesenchymal stem cell (MSC) is a promising tool for the therapy of immune disorders. However, their efficacy and mechanisms in treating allergic skin disorders are less verified. We sought to investigate the therapeutic efficacy of human umbilical cord blood-derived MSCs (hUCB-MSCs) against murine atopic dermatitis (AD) and to explore distinct mechanisms that regulate their efficacy. AD was induced in mice by the topical application of Dermatophagoides farinae. Naive or activated-hUCB-MSCs were administered to mice, and clinical severity was determined. The subcutaneous administration of nucleotide-binding oligomerization domain 2 (NOD2)-activated hUCB-MSCs exhibited prominent protective effects against AD, and suppressed the infiltration and Degranulation of mast cells (MCs). A β-hexosaminidase assay was performed to evaluate the effect of hUCB-MSCs on MC Degranulation. NOD2-activated MSCs reduced the MC Degranulation via NOD2-cyclooxygenase-2 signaling. In contrast to bone marrow-derived MSCs, hUCB-MSCs exerted a cell-to-cell contact-independent suppressive effect on MC Degranulation through the higher production of prostaglandin E2 (PGE2 ). Additionally, transforming growth factor (TGF)-β1 production from hUCB-MSCs in response to interleukin-4 contributed to the attenuation of MC Degranulation by downregulating FceRI expression in MCs. In conclusion, the subcutaneous application of NOD2-activated hUCB-MSCs can efficiently ameliorate AD, and MSC-derived PGE2 and TGF-β1 are required for the inhibition of MC Degranulation.